In 2016 was created Jinggong Hongyuan, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Beijing. The venture was found in Asia in China.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2017.
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the Jinggong Hongyuan, startups are often financed by General Technology Venture Capital. The meaningful sponsors for the fund in investment in the same round are ZGC Group, Shanghai Creation Investment, Proxima Ventures Ltd.
Among the various public portfolio startups of the fund, we may underline Cygnus Biosciences For fund there is a match between the location of its establishment and the land of its numerous investments - China. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Therapeutics.
Related Funds
Fund Name | Location |
Anchorage Capital Partners | Australia, New South Wales, Sydney |
BlueJay Syndicate | Baltimore, Maryland, United States |
BULB Japan | Japan, Tokyo |
Chicago Early Growth Ventures (CEGV) | Chicago, Illinois, United States |
Financial Academy | Japan, Tokyo |
Gemini Capital Management Fund | Seattle, United States, Washington |
Goodwood Capital Fund | Canada, Ontario, Toronto |
Heartland Farms | Hancock, United States, Wisconsin |
JHF Investment | Beijing, Beijing, China |
Kesheng Chuangtou | China, Shanghai |
NYC Media Lab | Brooklyn, New York, United States |
Oaktree Specialty Lending Corp. | New York, United States, White Plains |
Paradice Investment Management | - |
Paras Aerospace | - |
Ricebank | China, Hangzhou, Zhejiang |
Rotor Capital Partners | Delaware, Lewes, United States |
SIG Global India Fund | - |
Staley Capital | Massachusetts, United States, Wellesley |
XLHEALTH | Berlin, Berlin, Germany |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Cygnus Biosciences | $19M | 14 Nov 2017 | Changping District, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Cygnus Biosciences | $19M | 14 Nov 2017 | Changping District, Beijing, China |